Genomic Cancer Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Genomic Profiling Tests, Liquid Biopsy Tests, Companion Diagnostic Tests, Pharmacogenomic Tests, Hereditary Cancer Tests, Others), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Others), By End User (Hospitals, Diagnostic Laboratories, Academic and Research Institutions, Cancer Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 14.48 Billion
CAGR (2026-2031)	10.51%
Fastest Growing Segment	Liquid Biopsy
Largest Market	North America
Market Size (2031)	USD 26.37 Billion

Market Overview

The Global Genomic Cancer Testing Market will grow from USD 14.48 Billion in 2025 to USD 26.37 Billion by 2031 at a 10.51% CAGR. The Global Genomic Cancer Testing Market comprises diagnostic solutions utilized to analyze genetic alterations in tumor DNA for guiding personalized oncology treatment. Key drivers propelling this sector include the widespread adoption of precision medicine and a critical rise in oncological incidence rates which necessitate accurate molecular profiling. According to the American Cancer Society, in 2024, 2,001,140 new cancer cases are projected to occur in the United States. This figure exemplifies the growing burden of disease that fuels the demand for advanced diagnostic interventions and targeted therapies.

Technological adoption further supports market growth by enabling simultaneous detection of multiple mutations to streamline therapeutic decision making. Providers increasingly prioritize these comprehensive insights to optimize patient survival rates through tailored care pathways. Nevertheless, the market faces a significant challenge regarding inconsistent reimbursement policies and high implementation costs, which continue to impede equitable access and limit expansion across cost sensitive healthcare systems.

Key Market Drivers

The integration of Artificial Intelligence in Genomic Analysis is revolutionizing the speed and accuracy of tumor profiling, directly addressing the data complexity inherent in next-generation sequencing. By leveraging machine learning algorithms, laboratories can now interpret vast genomic datasets more efficiently, identifying rare mutations and therapeutic targets that traditional methods might miss. This technological synergy is driving substantial commercial growth as providers scale their diagnostic capabilities to meet clinical needs. According to Tempus AI, November 2025, in the 'Q3 2025 Quarterly Report', the company achieved a net revenue of $334.2 million, marking an 85% increase year-over-year primarily driven by its AI-enabled data and genomics services. Such rapid expansion underscores the critical role of computational power in making precision oncology scalable for widespread clinical application.

Concurrently, the Increasing Preference for Non-Invasive Liquid Biopsy is expanding market access by offering a patient-friendly alternative to tissue sampling. These blood-based tests allow for continuous monitoring of treatment response and early detection of recurrence without the risks associated with surgical biopsies. This shift toward less invasive modalities is evidenced by surging test volumes across major providers. According to Guardant Health, October 2025, in the 'Third Quarter 2025 Financial Results', oncology test volume increased by 40% year-over-year, reaching approximately 74,000 tests. This adoption is essential to manage the escalating global healthcare demand. According to The ASCO Post, October 2025, referencing 'The Cancer Atlas, 4th Edition', the worldwide cancer burden is projected to rise by approximately 74% from 2022 to 2050, ballooning to 33 million new cases annually, necessitating scalable diagnostic solutions like liquid biopsy.

Download Free Sample Report

Key Market Challenges

Inconsistent reimbursement policies and high implementation costs serve as a primary restraint on the growth of the Global Genomic Cancer Testing Market. Insurers frequently classify comprehensive genomic profiling as experimental or medically unnecessary, resulting in coverage denials that place a heavy financial burden on patients. When reimbursement pathways are unclear or restrictive, clinical laboratories cannot recover the substantial capital invested in these tests, and physicians are discouraged from ordering diagnostics that patients cannot afford. This economic misalignment directly reduces the volume of tests processed and limits market penetration, particularly in regions with cost-sensitive healthcare infrastructure.

The impact of these financial barriers is further amplified by administrative hurdles that delay or prevent access to care. According to the American Medical Association, in 2024, 78% of physicians reported that prior authorization policies frequently led to patients abandoning recommended tests or treatments. This high rate of test abandonment demonstrates how restrictive payer policies directly curtail market revenue. Without consistent coverage, the adoption of genomic testing remains confined to well-funded academic centers, hindering the broader expansion necessary for sustained market growth.

Key Market Trends

The Decentralization of Next-Generation Sequencing to In-House Clinical Labs is fundamentally altering the market by enabling hospitals to bring genomic testing on-site. Historically, complex molecular profiling was outsourced to reference laboratories, often causing turnaround delays that hindered rapid therapeutic decision-making. Now, the availability of user-friendly, high-throughput desktop sequencers and regulatory-approved kitted solutions empowers local institutions to conduct comprehensive profiling internally, facilitating immediate access to patient data. This shift toward local adoption is driving significant consumption of clinical sequencing reagents as providers take control of their diagnostic workflows. According to Illumina, November 2024, in the 'Third Quarter 2024 Financial Results', sequencing consumables revenue increased by 7% year-over-year to $741 million, a growth trajectory attributed to the rising clinical utilization of their sequencing platforms in hospital settings.

Concurrently, the Proliferation of Companion Diagnostic (CDx) Collaborations is solidifying the link between pharmaceutical development and diagnostic testing. Drug developers are increasingly partnering with diagnostic firms early in clinical trials to co-develop validated assays, ensuring that novel targeted therapies are launched alongside ready-to-use biomarker tests. This collaborative strategy accelerates patient identification and maximizes the immediate clinical uptake of new drugs by providing physicians with necessary prescription tools upon approval. The commercial impact of this model is substantial, as it aligns diagnostic revenue growth directly with pharmaceutical pipelines. According to Qiagen, November 2024, in the 'Q3 2024 Financial Results', sales in the Diagnostic Solutions product group rose 10% at constant exchange rates, a performance explicitly driven by the expansion of partnerships for companion diagnostic co-development.

Segmental Insights

The liquid biopsy segment represents the fastest-growing category in the global genomic cancer testing market, driven by its distinct advantages over traditional surgical procedures. This growth is largely attributed to the non-invasive nature of the test, which enables repeated sampling and real-time monitoring of disease progression with minimal patient risk. Additionally, the increasing validation and approval of blood-based diagnostics by the U.S. FDA have strengthened clinical confidence and expanded reimbursement avenues. These factors collectively encourage widespread adoption by healthcare providers, positioning liquid biopsy as a pivotal component of modern oncology.

Regional Insights

North America maintains a dominant position in the global genomic cancer testing market due to its established healthcare infrastructure and the concentrated presence of major biotechnology companies. The region benefits from substantial government funding for precision medicine research and a high prevalence of cancer cases that drive demand for diagnostic solutions. This leadership is reinforced by a supportive regulatory environment, where the U.S. Food and Drug Administration (FDA) provides clear guidelines for the approval of next-generation sequencing tests. These factors collectively accelerate the commercial adoption of genomic profiling across the region.

Recent Developments

• In September 2025, Illumina entered into partnerships with multiple global pharmaceutical companies to develop companion diagnostics enabled on its TruSight Oncology Comprehensive genomic profiling test. These collaborations focused on identifying KRAS alterations, a genetic marker associated with uncontrolled cell growth in various cancers. The initiative aimed to expand the number of tumor-agnostic companion diagnostic claims, facilitating broader patient access to precision oncology treatments. The Vice President and Head of Clinical Solutions at Illumina stated that developing these diagnostics would assist clinicians in matching patients with appropriate targeted therapies regardless of the tumor's origin.
• In October 2024, Exact Sciences announced that the U.S. Food and Drug Administration approved Cologuard Plus, its next-generation multitarget stool DNA test. The approval was supported by data from the pivotal BLUE-C study, which demonstrated that the test achieved 95% overall cancer sensitivity and 94% specificity. The test was designed to minimize false positives and subsequently reduce unnecessary follow-up colonoscopies compared to the original version. The Chairman and CEO of Exact Sciences highlighted that the new test established a higher performance standard for non-invasive colorectal cancer screening and would be launched commercially in 2025.
• In July 2024, Guardant Health received approval from the U.S. Food and Drug Administration for its Shield blood test as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. This authorization marked the first time a blood test was approved for this purpose, allowing healthcare providers to offer it alongside other non-invasive screening methods. The test satisfied the performance requirements necessary for Medicare coverage. The Co-CEO of Guardant Health noted that the approval would help improve screening rates by providing a convenient, blood-based alternative to traditional methods like colonoscopy.
• In March 2024, Thermo Fisher Scientific and Bayer announced a strategic collaboration to develop next-generation sequencing-based companion diagnostic assays. This partnership focused on identifying patients who could benefit from Bayer’s precision cancer therapies through decentralized genomic testing. The companies agreed to co-develop these diagnostics utilizing Thermo Fisher’s Oncomine Dx Express Test on the Ion Torrent Genexus Dx System, a platform designed to provide rapid results from tumor or liquid biopsy samples. The President of Clinical Next-Generation Sequencing and Oncology at Thermo Fisher Scientific emphasized that the collaboration would enhance patient access to targeted treatment options.

Key Market Players

• Illumina, Inc.
• F. Hoffmann-La Roche Ltd
• QIAGEN NV
• Merck KGaA
• Abbott Laboratories Inc.
• Novogene Co., Ltd.
• Guardant Health, Inc.
• Personal Genome Diagnostics Inc.
• Thermo Fisher Scientific Inc.
• NeoGenomics Laboratories, Inc.

By Test Type	By Technology	By End User	By Region
Genomic Profiling Tests Liquid Biopsy Tests Companion Diagnostic Tests Pharmacogenomic Tests Hereditary Cancer Tests Others	Next-Generation Sequencing (NGS) Polymerase Chain Reaction (PCR) Fluorescence In Situ Hybridization (FISH) Immunohistochemistry (IHC) Others	Hospitals Diagnostic Laboratories Academic and Research Institutions Cancer Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Genomic Cancer Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Genomic Cancer Testing Market, By Test Type:

• Genomic Profiling Tests
• Liquid Biopsy Tests
• Companion Diagnostic Tests
• Pharmacogenomic Tests
• Hereditary Cancer Tests
• Others

• Genomic Cancer Testing Market, By Technology:

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescence In Situ Hybridization (FISH)
• Immunohistochemistry (IHC)
• Others

• Genomic Cancer Testing Market, By End User:

• Hospitals
• Diagnostic Laboratories
• Academic and Research Institutions
• Cancer Centers
• Others

• Genomic Cancer Testing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE